Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TAK-003 in Healthy Volunteers
NCT01511250Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of dengue tetravalent vaccine (live, attenuated) in dengue fever (10 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Solicited Local (Injection Site) Adverse Events, Number of Participants With Solicited Systemic Adverse Events and 2 more. Started Nov 2011; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT01511250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511250.